



# INTERPRETATION OF DYNAMIC X-NUCLEI EXPERIMENTS WITH METABOLIC MODELLING

Bernard Lanz, PhD  
*CIBM MRI EPFL*

10.04.2025



PHYS-770

CIBM translational MR neuroimaging & spectroscopy

**EPFL**

# IN VIVO STUDIES OF BRAIN ACTIVITY

- Electromagnetic activity (action potential):
  - Electroencephalography (EEG)
  - Magnetoencephalography (MEG)
- Oxygen demand and hemodynamic response (oxy/deoxyhemoglobin)
  - Functional magnetic resonance imaging (fMRI)
- Energy metabolism (use of plasma energy substrates)
  - Dynamic magnetic resonance spectroscopy:
    - $^1\text{H}$  MRS (fMRS) without tracer injection
    - $^{13}\text{C}$  MRS with tracer injection
    - $^{15}\text{N}$  MRS with tracer injection
    - $^{31}\text{P}$  MRS without tracer injection
  - Radionuclides emission tomography (PET, SPECT)



# WHAT CAN WE MEASURE WITH MRS ?

*In vivo* magnetic resonance spectroscopy (MRS)  
gives extended chemical information on the compounds involved  
in brain metabolism and biochemical processes

## $^1\text{H}$ MRS spectrum:



Measures total concentrations of  
more than 20 compounds at high field  
(static acquisition in one voxel)

## Extend spatial information:

Magnetic resonance spectroscopic imaging (MRSI)

## Extend temporal information:

Dynamic magnetic resonance spectroscopy (typically X-nuclei),  
to measure metabolic fluxes / reactions




Courtesy of D Simicic, C Cudalbu

*It is an equilibrium information on the compounds  
Does not carry information on their interaction*





# UNDERLYING BIOCHEMICAL MECHANISMS ?







# UNDERLYING BIOCHEMICAL MECHANISMS ?

## TCA cycle: (or Krebs cycle)

Main oxidative reaction chain producing ATP for the various cellular needs in energy.




# BRAIN ENERGY METABOLISM: UNDERLYING BIOCHEMICAL MECHANISMS ?




# BIOCHEMICAL MOTIVATIONS

## Network:







# MAIN BIOCHEMICAL PATHWAYS IN BRAIN ENERGY METABOLISM





# OVERVIEW $^{13}\text{C}$ MRS *IN VIVO*

## The Carbon nucleus

- Spin  $I=1/2$




- Natural abundance



- Low sensitivity


$$\gamma(^{13}\text{C}) = 10.7 \text{ MHz/T}$$

$$(\gamma(^1\text{H}) = 42.6 \text{ MHz/T})$$



# $^{13}\text{C}$ MRS

## Separate detection of carbon positions







## Separate detection of carbon positions

### Large chemical shift:

- + Good spectral resolution
- + Flat baseline
- Large chemical shift artefacts












Methine groups










Methylene groups



Carboxyl / amide groups (C5 and C1) (170-185 ppm)


## Detection of multiple $^{13}\text{C}$ labelling

Glutamate	C4 resonance	C3 resonance	C2 resonance
$\begin{array}{c} \text{COO}^- \\   \\ {}^{13}\text{CH}_2 \\   \\ \text{HC}-\text{H} \\   \\ \text{HC}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ {}^{13}\text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{HC}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ {}^{13}\text{CH}_2 \\   \\ \text{HC}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ {}^{13}\text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ \text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{HC}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			

Glutamate	C4 resonance	C3 resonance	C2 resonance
$\begin{array}{c} \text{COO}^- \\   \\ \text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ \text{CH}_2 \\   \\ \text{HC}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ \text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ \text{CH}_2 \\   \\ \text{HC}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ {}^{13}\text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ \text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ {}^{13}\text{COO}^- \end{array}$			
$\begin{array}{c} \text{COO}^- \\   \\ {}^{13}\text{CH}_2 \\   \\ \text{H}^{13}\text{C}-\text{H} \\   \\ \text{H}^{13}\text{C}-\text{NH}_2 \\   \\ {}^{13}\text{COO}^- \end{array}$			

# $^{13}\text{C}$ MRS NMR SIGNAL STRENGTH

- Zeeman energy:  $\gamma_C \cong \frac{1}{4} \gamma_H$





Boltzmann distribution:  $(n_\alpha - n_\beta) \approx \left( \frac{n h \gamma B_0}{2kT} \right)$

- Amplitude of the magnetization:  $M_0 = (n_\alpha - n_\beta) \mu_z = (n_\alpha - n_\beta) \gamma \frac{h}{2}$
- Total magnetization:  $M_0 = n \frac{1}{2} (\gamma h)^2 \left( \frac{B_0}{2kT} \right) \propto \gamma^2$

$$M_0(^{13}\text{C}) \cong \frac{1}{16} M_0(^1\text{H})$$



# THEORETICAL GAIN IN SNR



	<sup>1</sup> H-[ <sup>13</sup> C]MRS	Polarization transfer <sup>13</sup> C MRS
<u>Polarization</u> $\Delta E \propto \gamma$	<sup>1</sup> H	<sup>1</sup> H
<u>Magnetic moment</u> $\mu_z \propto \gamma$	<sup>1</sup> H	<sup>13</sup> C
<u>Detection sensitivity</u> $emf \propto freq. \propto \gamma$ $Noise \propto \gamma^{1/2}$	<sup>1</sup> H	<sup>13</sup> C
Overall SNR	$\propto \gamma_H^{5/2} (32x)$	$\propto \gamma_H \gamma_C^{3/2} (4x)$


(neglecting T1 saturation effects)

# $^{13}\text{C}$ MRS ACQUISITION STRATEGIES

## Indirect $^{13}\text{C}$ detection



### ■ Indirect $^1\text{H}$ - $^{13}\text{C}$ localized MRS detection

- High sensitivity of  $^1\text{H}$  detection  
(of advantage for higher temporal resolution / lower enrichment studies)  
-> lower chemical shift range



Indirect  $^{13}\text{C}$  MRS spectroscopy:  
( $[2-^{13}\text{C}]$  Ace infusion)

BISEP-SPECIAL  $^1\text{H}$ - $^{13}\text{C}$  MRS (at 14T)



Xin et al., MRM, 2010


# $^{13}\text{C}$ MRS ACQUISITION STRATEGIES

## Direct $^{13}\text{C}$ detection

### ■ Direct $^{13}\text{C}$ localized MRS detection with polarization transfer


- Higher chemical shift range of  $^{13}\text{C}$  spectra (many carbon resonances measurable)

-> labelling positions clearly dissociable




#### Localized DEPT:

Henry et al.,  
MRM, 2003



#### $^{13}\text{C}$ MRS spectrum:

([1,6- $^{13}\text{C}$ ] Glc infusion  
rat, 9.4T, 320  $\mu\text{l}$ , last 50 min)





# MISSING INTERNAL REFERENCE

$^1\text{H}$  MRS : water signal

- Frequency reference
- Power calibration
- Concentration reference
- ...




# MISSING INTERNAL REFERENCE

$^{13}\text{C}$  MRS : no carbon in water



- No frequency reference
- No reference for power calibration
- No concentration reference
- ...



# $^{13}\text{C}$ -FORMIC ACID CALIBRATION



**Formic acid- $^{13}\text{C}$**   
95 wt. % in  $\text{H}_2\text{O}$ , 99 atom %  $^{13}\text{C}$




## $T_1$ relaxation:


Reduced from ~6 to **0.5 second** with Gd contrast agent (Dotarem)

$$\frac{1}{T_{1,obs}} = \frac{1}{T_1} + r_1[CA]$$

with  $[CA]$  the concentration of contrast agent.



## $^{13}\text{C}$ spectrum



# BRAIN METABOLIC MODELLING

Metabolic modelling is a two-step process.


1. The metabolic system is formalized as a schematic, taking into account the current physiological and biochemical knowledge on the biological system. It is adapted to the available information, since part of the system is not measurable or not relevant for the measured processes.

→ set of mathematical equations

2. The model is used to estimate the metabolic parameters involved in the studied metabolic process by fitting it to the experimental data.

- appropriateness of the model
- parameter values describing the current data
- precision of these estimations.

Feedback



- The study of brain metabolism with dynamic labelling studies is intrinsically linked with the use of a particular tracer.

Definitions: **A tracer** is defined as an isotope-labelled and detectable molecule, used to follow the fate of unlabelled chemical species that it is transformed into through metabolism.



**The tracee** is the corresponding unlabelled species, whose dynamics is of interest in the analysed metabolic process.

- The chemical structure of the tracer is commonly close to the chemical structure of the tracee (identical in the case of  $^{13}\text{C}$  MRS)

FDG / glucose       $[1,6-^{13}\text{C}]$ glucose / glucose       $[2-^{13}\text{C}]$ acetate / acetate




## Characteristics of the ideal tracer :

1. It should be detectable by the applied bioimaging measurement technique and should be measurable quantitatively as a concentration (mol of tracer/ g) or as a fractional enrichment ([amount of tracer] / [amount of tracer and tracee])
2. Its introduction should minimally affect the biochemical system that is studied
3. Its metabolism should be identical to the metabolism of the tracee
4. When entering a metabolic pool, it should mix uniformly and instantly throughout
5. The natural abundance of the tracer should be very low, to avoid additional measurement errors due to background contamination
6. It should provide chemical specificity, in the sense that the detection system should be able to determine in which molecule and in which position in this molecule the labelled isotope is located
7. It should be safe for the experimentalist and for the subject and should be detectable in the tissue in a non-destructive way
8. It should enable a site-specific detection, meaning that the researcher should be able to measure the uptake and metabolism of the tracer locally in any physical space of a chosen organ

# COMPARTMENTAL MODELLING


- The different biochemical species (or group of species) are modelled as idealized stores of substance called metabolic pools (also called labelling pools)
    - Describes molecules that share the same behaviour
    - Each pool is supposed homogeneous (instantaneous mixing of the tracer with the tracee, uniform volume distribution)
- The probability of leaving the labelling pool through any of the available effluxes is the same for all the molecules present in the pool




# OBJECTIVES OF THE MODEL

The objectives of a metabolic model can be the following:

- identification the structure of the system



- estimation of the value of the internal metabolic parameters and their precision




- prediction of the response of the system to external factors



# MATHEMATICAL DESCRIPTION OF COMPARTMENTAL MODELS

The elementary unit, the labelling pool :




- Represents a labelling position in a given molecule, or simply a labelled molecule
- Is characterized by :
  - Its total concentration (P) in  $[\mu\text{mol/g}]$
  - Its labelled concentration ( $P^*$ ) in  $[\mu\text{mol/g}]$  (typically  $^{13}\text{C}$ ), or equivalently by its fractional enrichment :  
[-], varying between 0 and 1

$$\text{FE} = \frac{P^*}{P}$$

# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

The labelling equations:



Mass balance equation:  $\frac{dP(t)}{dt} = \sum_i V_i^{in} - \sum_j V_j^{out}$  at metabolic steady-state

Labelling equation :  $\frac{dP^*(t)}{dt} = \sum_i V_i^{in} \cdot \underbrace{\frac{S_i^*(t)}{S}}_{FE} - \sum_j V_j^{out} \cdot \underbrace{\frac{P^*(t)}{P}}_{FE}$

In compartment modelling  
of PET data :

$$\frac{dP^*(t)}{dt} = \sum_i K_i^{in} \cdot S_i^*(t) - \sum_j K_j^{out} \cdot P^*(t) \quad \text{with } K_i^{in} = \frac{V_i^{in}}{S} \text{ and } K_j^{out} = \frac{V_j^{out}}{P}$$






# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

The measurement of the substrate concentration:

The arterial input function (AIF)




The AIF needs to be measured continuously over the entire infusion period or

The infusion protocol is designed to reach a desired input function.

# SIMPLE ONE-PRODUCT POOL EXAMPLE

The labelling equations:




$$\left\{ \begin{array}{l} \text{Mass balance equation : } \frac{dP(t)}{dt} = V_{in} - V_{out} = 0 \\ \text{Labelling equation : } \frac{dP^*(t)}{dt} = V_{in} \cdot \frac{S^*(t)}{S} - V_{out} \cdot \frac{P^*(t)}{P} \end{array} \right. \quad (\text{metabolic steady-state})$$

(we assume  $P^*(0) = 0$ )

# SIMPLE ONE-PRODUCT POOL EXAMPLE

The labelling equations:



$$\left\{ \begin{array}{l} \text{Mass balance equation : } \frac{dP(t)}{dt} = V_{in} + V_{dil} - V_{out} = 0 \quad (\text{metabolic steady-state}) \\ \text{Labelling equation : } \frac{dP^*(t)}{dt} = V_{in} \cdot \frac{S^*(t)}{S} - V_{out} \cdot \frac{P^*(t)}{P} \end{array} \right.$$

(we assume  $P^*(0) = 0$ )

# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

General equations for a compartmental model:

$$\left\{ \begin{array}{l} \text{Mass balance equation : } \frac{d}{dt} \begin{pmatrix} P_1(t) \\ P_2(t) \\ \dots \\ P_n(t) \end{pmatrix} = \begin{pmatrix} V_{S1} & V_{21} & \dots & V_{n1} \\ V_{S2} & V_{22} & \dots & V_{n2} \\ \dots & \dots & \dots & \dots \\ V_{Sn} & V_{2n} & \dots & V_{nn} \end{pmatrix} \begin{pmatrix} 1 \\ 1 \\ \dots \\ 1 \end{pmatrix} \text{ (metabolic steady-state)} \\ \text{Labelling equation : } \frac{d}{dt} \begin{pmatrix} P_1^*(t) \\ P_2^*(t) \\ \dots \\ P_n^*(t) \end{pmatrix} = \begin{pmatrix} V_{S1} & V_{21} & \dots & V_{n1} \\ V_{S2} & V_{22} & \dots & V_{n2} \\ \dots & \dots & \dots & \dots \\ V_{Sn} & V_{2n} & \dots & V_{nn} \end{pmatrix} \begin{pmatrix} S^*(t)/[S] \\ P_2^*(t)/[P_2] \\ \dots \\ P_n^*(t)/[P_n] \end{pmatrix} \end{array} \right. = \begin{pmatrix} 0 \\ 0 \\ \dots \\ 0 \end{pmatrix}$$

System of linear differential equations with constant coefficients



Numerical solutions

# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

## Solutions of the labelling equations system: ANALYTICAL ?

- The mass balance matrix equation fixes the relation between the fluxes (continuity of the system, no loss or creation of molecules in the system)
- The labelling matrix equation must be solved by taking into account the mass balance constraints
  - In order to decouple the system of differential equations, the labelling matrix needs to be diagonalised
  - The dimension of the matrix is equal to the number of pools in the model
  - This requires the factorization of the characteristic polynomial, of same degree as the dimension of the matrix

*“There is no general solution in radicals to polynomial equations of degree five or higher”*

Labelling equation :

$$\frac{d}{dt} \begin{pmatrix} P_1^*(t) \\ P_2^*(t) \\ \dots \\ P_n^*(t) \end{pmatrix} = \begin{pmatrix} V_{s1} & V_{21} & \dots & V_{n1} \\ V_{s2} & V_{22} & \dots & V_{n2} \\ \dots & \dots & \dots & \dots \\ V_{sn} & V_{2n} & \dots & V_{nn} \end{pmatrix} \begin{pmatrix} S^*(t) / [S] \\ P_2^*(t) / [P_2] \\ \dots \\ P_n^*(t) / [P_n] \end{pmatrix}$$



Numerical solutions

Niels Henrik Abel



(1802-1829)




# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

Niels Henrik Abel



(1802-1829)



## Démonstration

de l'impossibilité de la résolution générale des équations du  
cinquième degré.

Les géomètres se sont beaucoup occupés de la résolution générale des équations algébriques, et plusieurs d'entre eux ont cherché à en prouver l'impossibilité; mais si je ne me trompe pas, on n'a pas y réussi jusqu'à présent. J'ose donc espérer que les géomètres veulent recevoir avec bienveillance ce mémoire qui a pour but de remplir cette lacune dans la théorie des équations algébriques.

Soit

$$y^5 - ay^4 + by^3 - cy^2 + d - e = 0$$

l'équation générale du cinquième degré et supposons qu'elle est résoluble algébriquement c'est-à-dire qu'on peut exprimer  $y$  par une fonction des quantités  $a b c d$  et  $e$ , formée par des radicaux. Il est clair qu'on peut dans ce cas mettre  $y$  sous cette forme:

$$y = p + p_1 R^{\frac{1}{m}} + p_2 R^{\frac{2}{m}} + \dots + p_{m-1} R^{\frac{m-1}{m}}$$


$m$  étant un nombre premier et  $R p p_1 p_2$  etc. des fonctions de la même forme que  $y$ , et ainsi de suite jusqu'à ce qu'on parviendra à des fonctions rationnelles des quantités  $a b c d$  et  $e$ . On peut aussi supposer qu'il est impossible d'exprimer  $R^{\frac{1}{m}}$  par une fonction rationnelle des quantités  $a b$  etc.  $p p_1 p_2$  etc., et en mettant  $\frac{R}{p_1^m}$  au lieu de  $R$  il est clair qu'on peut faire  $p_1 = 1$ . On aura donc:

$$y = p + R^{\frac{1}{m}} + p_2 R^{\frac{2}{m}} + \dots + p_{m-1} R^{\frac{m-1}{m}}$$


# EXTRACTING METABOLIC PARAMETERS FROM THE EXPERIMENTAL DATA

- The mathematics needed in metabolic modelling can be schematically separated into two steps.
  - The first is to find a **general solution to the set of equations** that describes the biochemical model
  - The second is to find the **particular set of model parameters** that describe the observation.

→ REGRESSION



# REGRESSION



- A metabolic model is designed to explain the experimental observations and gives a number  $j$  of output functions  $f$  that describe the  $j$  dynamic datasets obtained from the measurement:

$$f_j(a_1, a_2, \dots, a_m, t)$$

- The most common measurement of proximity of the data and simulation is the least-squares criterion:

$$WRSS = \sum_{j=1}^J \sum_{i=1}^n w_j \left[ y_j(t_i) - f_j(a_1, a_2, \dots, a_m, t_i) \right]^2$$

where  $y_j(t_i)$  are the  $i$  sampling points of the  $j^{th}$  uptake curve,

$w_j$  the relative weight of the  $j^{th}$  curve in the regression. (typically,  $w_j = 1/Var_j$ )

- The precision of the parameter estimation can be estimated by error propagation from the regression in terms of the covariance matrix :

$$\mathbf{Cov}(\hat{\mathbf{a}}) = \begin{pmatrix} \text{Var}(\hat{a}_1) & \text{Cov}(\hat{a}_1, \hat{a}_2) & \dots & \text{Cov}(\hat{a}_1, \hat{a}_m) \\ \text{Cov}(\hat{a}_2, \hat{a}_1) & \text{Var}(\hat{a}_2) & \dots & \text{Cov}(\hat{a}_2, \hat{a}_m) \\ \dots & \dots & \dots & \dots \\ \text{Cov}(\hat{a}_m, \hat{a}_1) & \text{Cov}(\hat{a}_m, \hat{a}_2) & \dots & \text{Var}(\hat{a}_m) \end{pmatrix}$$

where  $\hat{a}_1, \hat{a}_2, \dots$ , are the optimized parameters of the system (metabolic fluxes)


# BASIC PRINCIPLES OF NON-LINEAR REGRESSION

## PARAMETER PRECISION AND CORRELATION

Similarly the correlation matrix of the parameters can be extracted

$$\mathbf{Corr}(\hat{\mathbf{a}}) = \begin{pmatrix} 1 & \frac{\text{Cov}(\hat{a}_1, \hat{a}_2)}{SD(\hat{a}_1) SD(\hat{a}_2)} & \cdots & \frac{\text{Cov}(\hat{a}_1, \hat{a}_m)}{SD(\hat{a}_1) SD(\hat{a}_m)} \\ \frac{\text{Cov}(\hat{a}_2, \hat{a}_1)}{SD(\hat{a}_2) SD(\hat{a}_1)} & 1 & \cdots & \frac{\text{Cov}(\hat{a}_2, \hat{a}_m)}{SD(\hat{a}_2) SD(\hat{a}_m)} \\ \cdots & \cdots & \cdots & \cdots \\ \frac{\text{Cov}(\hat{a}_m, \hat{a}_1)}{SD(\hat{a}_m) SD(\hat{a}_1)} & \frac{\text{Cov}(\hat{a}_m, \hat{a}_2)}{SD(\hat{a}_m) SD(\hat{a}_2)} & \cdots & 1 \end{pmatrix}$$

- Non-linearity of the system (model)
  - > Sometimes, small effects on the noise of the data can have huge impact on the estimated parameters
- An alternative method to evaluate the precision and correlation of the model parameters is Monte Carlo simulation






# WARNINGS

- Although many optimized algorithm have been developed for non-linear regression, it is in practice never possible to be **completely sure** that the found optimum is a global minimum.
- The fact that the model functions fit the experimental data is necessary, but **not sufficient**.
  - Precision of the model parameters  
(sensitivity of the measurement to the given parameters)
  - Correlation between the parameters  
(close to  $\pm 1$   $\rightarrow$  parameters not individually identifiable)
- A compartmental model is therefore as good as the assumptions that are incorporated in it.

# BIOCHEMICAL MOTIVATIONS

## Brain energy metabolism




### In vivo $^{13}\text{C}$ NMR spectroscopy:

- $^{13}\text{C}$  natural abundance is only 1.1%
- $^{13}\text{C}$  can be used as a **tracer** by infusing  $^{13}\text{C}$ -enriched substrates

# BRAIN ENERGY METABOLISM STUDIED WITH $^{13}\text{C}$ MRS


THE TRACER:  $[1,6\text{-}^{13}\text{C}]$  GLUCOSE OR  $[1\text{-}^{13}\text{C}]$  GLUCOSE

$[1,6\text{-}^{13}\text{C}]$  glucose




Glycolysis

2 x more enrichment




TCA cycle,  
Lactate metabolism

$[1\text{-}^{13}\text{C}]$  glucose



Glycolysis




TCA cycle,  
Lactate metabolism



# BRAIN ENERGY METABOLISM STUDIED WITH $^{13}\text{C}$ MRS

## TCA CYCLE METABOLISM OF [1,6- $^{13}\text{C}$ ] GLUCOSE

### Neuronal TCA cycle (2nd turn)




# BRAIN ENERGY METABOLISM STUDIED WITH $^{13}\text{C}$ MRS

## TCA CYCLE METABOLISM OF $[1,6\text{-}^{13}\text{C}]$ GLUCOSE


### Glial-specific reaction

- *pyruvate carboxylase*



# BRAIN ENERGY METABOLISM STUDIED WITH $^{13}\text{C}$ MRS

## the two-compartment model



In  $^{13}\text{C}$  MRS, the metabolites with sufficient concentration are measured ( $> 1\text{mM}$ )

→ **Glu, Gln, Asp and Lac**


[1] Gruetter et al., *Am. J. Physiol. Endocrinol. Metab.*, 2001

[2] Sibson et al., *J. Neurochem.*, 2001




# TWO-COMPARTMENT MODELING OF [1,6-<sup>13</sup>C] GLUCOSE BRAIN METABOLISM

1<sup>st</sup> TCA cycle turn labeling :




# TWO-COMPARTMENT MODELING OF [1,6-<sup>13</sup>C] GLUCOSE BRAIN METABOLISM

2<sup>nd</sup> TCA cycle turn labeling :




# TWO-COMPARTMENT MODELING OF [1,6-<sup>13</sup>C] GLUCOSE BRAIN METABOLISM

2<sup>nd</sup> TCA cycle turn labeling :



# TWO-COMPARTMENT MODELING OF [1,6-<sup>13</sup>C] GLUCOSE BRAIN METABOLISM

Dilution through PC:




# TWO-COMPARTMENT MODELING OF [1,6-<sup>13</sup>C] GLUCOSE BRAIN METABOLISM



## Labelling through PC:

Separate measurement of the C3 and C2 positions of Glu and Gln is required for a complete description of the 2-compartment model.

<sup>13</sup>C = ○  
<sup>12</sup>C = ●



# TWO-COMPARTMENT MODELLING OF BRAIN GLUCOSE METABOLISM



$$\frac{dP(t)}{dt} = \sum_i V_i^{in} - \sum_j V_j^{out} = 0$$

$$\frac{dP^*(t)}{dt} = \sum_i V_i^{in} \cdot \frac{S_i^*(t)}{S} - \sum_j V_j^{out} \cdot \frac{P^*(t)}{P}$$

In <sup>13</sup>C MRS, the metabolites with sufficient concentration are measured (> 1mM)

→ **Glu, Gln, Asp and Lac**

Each labelling position is described by a mass balance equation and a labelling equation





# [1,6-<sup>13</sup>C<sub>2</sub>] GLUCOSE DYNAMIC MRS STUDIES

## METHODS

### Experimental protocol:



- Fasted Sprague-Dawley rats (n=6) anesthetized with **alpha-chloralose** infusion
- A bolus of **99% enriched [1,6-<sup>13</sup>C<sub>2</sub>] glucose** is given over a 5 min period (based on the measured basal glycemia) and followed by constant infusion of **70% enriched [1,6-<sup>13</sup>C<sub>2</sub>] glucose**
- Generates a « **step function** » shaped glucose fractional enrichment in blood (**FE=70%**)
- Saturate glucose transport






# [1,6-<sup>13</sup>C<sub>2</sub>] GLUCOSE DYNAMIC MRS STUDIES

## METHODS

### Workflow:



# [1,6-<sup>13</sup>C<sub>2</sub>] GLUCOSE DYNAMIC MRS STUDIES

## METHODS

→ separate measurement of the labeling turnover:

In glutamate :

GluC4  
GluC3  
GluC2


In glutamine :

GlnC4  
GlnC3  
GlnC2

In aspartate:

AspC3  
AspC2

(time resol.= 5.3 min)





# [1,6-<sup>13</sup>C] GLUCOSE DYNAMIC MRS STUDIES AT 14T

## METHODS

### Results :

Two-compartmental model fitted to the experimental turnover curves.



$V_g$	0.23 +- 0.02
$V_x^g$	0.17 +- 0.06
$V_{nt}$	0.12 +- 0.01
$V_{tca}^n$	0.44 +- 0.01
$V_x^n$	0.76 +- 0.07
$V_{pc}$	0.07 +- 0.01


[ $\mu\text{mol/g/min}$ ]

# TWO-COMPARTMENT MODELLING

## OF [1,6-<sup>13</sup>C] GLUCOSE DYNAMIC MRS STUDIES AT 14T

### Results :

Characterization of brain oxidative metabolism.




$V_g$	0.23	+-	0.02
$V_x^g$	0.17	+-	0.06
$V_{nt}$	0.12	+-	0.01
$V_{tca}^n$	0.44	+-	0.01
$V_x^n$	0.76	+-	0.07
$V_{pc}$	0.07	+-	0.01
[ $\mu\text{mol/g/min}$ ]			

# EXTENSION OF IN VIVO $^{13}\text{C}$ STUDIES TO MICE

Rat (~270 g)  
Blood volume  $\approx$  15 ml




**Voxel 320  $\mu\text{L}$**   
5x8x8mm<sup>3</sup>



Mouse (~30 g)  
Blood volume  $\approx$  2.5 ml



**Voxel 112  $\mu\text{L}$**   
3.6x6.9x4.5mm<sup>3</sup>



## Additional difficulties in mice studies:

- smaller brain
  - smaller VOI and -> **low SNR**
  - Tissue inhomogeneities -> **difficult  $B_0$  shimming**
- small blood volume
  - Blood sampling in the magnet almost impossible -> **standardization of the input function or image-derived input function**

# CURRENT PROJECTS:

## EXTENSION OF IN VIVO $^{13}\text{C}$ STUDIES TO MICE

### Methods:

#### Animals and physiology:


- Nude male mice (8weeks old, 20-30g, n=3)
- 7 hours fasted
- Isoflurane anaesthesia (1-2%)

#### Infusion protocol (target FE = 70%, metabolic steady-state):

- Tail vein catheter
- 5 min exponential bolus of 99%-enriched  $[1,6-^{13}\text{C}_2]$  Glc
- 5 hours adjustable continuous infusion of 70%-enriched  $[1,6-^{13}\text{C}_2]$  Glc (target glycemia = 300mg/dL)

#### Data acquisition:

- Voxel 112 $\mu\text{L}$
- 14.1 Tesla system (Varian/Magnex)
- Home-built surface coil
- Semi-adiabatic DEPT sequence




# EXTENSION OF IN VIVO $^{13}\text{C}$ STUDIES TO MICE

## Results:

### IN VIVO data

32min acq. after 4.5h infusion  
SNR= 16

Voxel 112 $\mu\text{L}$   
3.6x6.9x4.5mm<sup>3</sup>









# EXTENSION OF IN VIVO $^{13}\text{C}$ STUDIES TO MICE

Results:

**Glutamate** and **Glutamine**

(temp. resol = 10min):




**Voxel 112 $\mu\text{L}$**   
3.6x6.9x4.5mm<sup>3</sup>




Fluxes	$V_g$	$V_{PC}$	$V_{NT}$	$V_{tca}^n$	$V_x$	$V_{dil}^g$
[ $\mu\text{mol/g/min}$ ]	0.11	0.051	0.21	0.33	0.20	0.82
SD	0.02	0.005	0.03	0.02	0.03	0.04

# THREE-COMPARTMENT MODEL

## Extension to inhibitory neuronal metabolism




# DYNAMIC NUCLEAR POLARISATION EXPERIMENTS



Ardenkjær-Larsen et al. 2003 PNAS

- Short life-time - metabolic pathways ↓
- $T_1$  relaxation - labelled substrates ↓

## State-of-the art metabolic model



## Adjusted parameters

### TARGET

- Metabolic isotope exchanges  
(Biochemical parameters)
- Magnetization decay through successive pulsing.  
(Technical parameter)
- $T_1$  relaxation  
(Physical parameter)

Kazan et al MRM 2013

# DYNAMIC NUCLEAR POLARISATION EXPERIMENTS

$$\frac{dPP}{dt} = -(R_p + k_{pl})PP(t) + k_{lp}LP(t) + K_{ip}C_P(t) \quad [2]$$


$$\frac{dLP}{dt} = k_{pl}PP(t) - (R_l + k_{lp})LP(t) \quad [3]$$

$$\frac{dPL}{dt} = -(R_p + k_{pl})PL(t) + k_{lp}LL(t) \quad [4]$$

$$\frac{dLL}{dt} = k_{pl}PL(t) - (R_l + k_{lp})LL(t) + K_{il}C_L(t) \quad [5]$$

$$R_{p/l} = \frac{1}{T_{1py/la}} + \frac{[1 - \cos(\theta)]}{TR} + k_{po/lo}$$

## State-of-the art metabolic model





## Adjusted parameters

### TARGET



- Metabolic isotope exchanges  
(Biochemical parameters)
- Magnetization decay through successive pulsing.  
(Technical parameter)
- $T_1$  relaxation  
(Physical parameter)

# TOWARDS QUANTITATIVE METABOLIC MODELLING IN HYPERPOLARIZED $^{13}\text{C}$ -GLUCOSE EXPERIMENTS



Article

## Measuring Glycolytic Activity with Hyperpolarized $[^2\text{H}_7, \text{U-}^{13}\text{C}_6]$ D-Glucose in the Naive Mouse Brain under Different Anesthetic Conditions


Emmanuelle Flatt <sup>1,†</sup>, Bernard Lanz <sup>1,†</sup>, Yves Pilloud <sup>2</sup>, Andrea Capozzi <sup>1</sup> , Mathilde Hauge Lerche <sup>3</sup>, Rolf Gruetter <sup>1</sup> and Mor Mishkovsky <sup>1,\*</sup> 

### Dynamic parameters

- Metabolic isotope exchanges  
(Biochemical parameters)
- Magnetization decay through successive pulsing.  
(Technical parameter)
- $T_1$  relaxation  
(Physical parameter)

# TOWARDS QUANTITATIVE METABOLIC MODELLING IN HYPERPOLARIZED $^{13}\text{C}$ -GLUCOSE EXPERIMENTS

## Sensitivity study (effect prediction)



Nominal values:

$[\text{Lac}] = 4 \mu\text{mol/g}$







$\text{CMR}_{\text{Glc}} = 0.25 \mu\text{mol/g/min}$

$\text{TR} = 1\text{s}$

$\text{Lac } R_1 = 1/18 \text{ s}^{-1} \text{ F.A.} = \pi/7$

$\text{Pyr } R_1 = 1/18 \text{ s}^{-1} \text{ F.A.} = \pi/7$

$\text{Glc } R_1 = 1/14 \text{ s}^{-1} \text{ F.A.} = \pi/120$   
(and apparent  $\text{TR} = 8\text{s}$ )






## Conclusion:

HP  $[^2\text{H}_7, \text{U-}^{13}\text{C}_6]$  Glc reports on **de novo Lac synthesis** and is **sensitive to  $\text{CMR}_{\text{Glc}}$** .

# QUANTITATIVE CMR<sub>GLC</sub> MAPPING WITH PRECLINICAL PET


## CIBM small animal PET scanner

Gamma Medica-Ideas, Inc.




### LabPET4 :

ring diameter :	15.6 cm
Aperture / Transverse field of view:	11 cm
Axial field of view:	3.7 cm
Number of APD Detectors:	1536





# QUANTIFICATION OF THE PET RESULTS



Coincidence list -> Remove false coincidences

**Histogramming** (Time frames)

Sinogram -> Correct for tissue absorption

**Reconstruction**

Image in counts/s/voxel

**Quantitative calibration**

(based on phantom measurements)

Image in Bq/ml



Intensity of the image depends on:

- the real uptake of tracer
- the injected dose and the weight (or volume) of the subject.

Standardized uptake value (semi-quantitative static parameter):  

$$\text{SUV (VOI)} = \frac{\text{activity density [Bq/ml]} * \text{subject weight [g]}}{\text{injected activity [Bq]}}$$


Lines of response for a given angle





# GLUCOSE CONSUMPTION MEASURED WITH FDG-PET


Fluorodeoxyglucose (FDG) -> glucose metabolism



Fluorodeoxyglucose

FDG half-life : 110 min


Mean free path the emitted  $\beta^+$  in water :  $\sim 1\text{mm}$



PET detectors:  
Scintillator + photomultiplier

# PARTICULARITY OF FDG


In the particular case of FDG, there is actually no «cold» tracer present in the system.



→ direct conversion of activity (in kBq/ml) to concentration is possible.

$$A(t) = A_0 \exp\left(\frac{-\ln(2) t}{T_{1/2}}\right)$$

$$C(t) = \frac{100}{96.86} \int_t^\infty A(t') dt' = \frac{100}{96.86} A(t) \left( \frac{T_{1/2}}{\ln(2)} \right)$$




With  $A \cong 500$  kBq/ml


→  $C \cong 5 \cdot 10^9$  molecules/ml  $\cong 8$  pmol/l

# METABOLISM OF FDG

BBB / Cell membrane




Fluorodeoxyglucose  
FDG



FDG-6P



# MODELLING OF GLUCOSE AND FDG METABOLISM:




PET  
measured  
quantity

$$C_i^*(t) = \frac{k_1^*}{k_2^* + k_3^*} \left( (k_2^* + k_3^*) e^{-(k_2^* + k_3^*)t} \right) \otimes C_p^*(t) \quad ) = 0$$

$$C_m^*(t) = \frac{k_1^* k_3^*}{k_2^* + k_3^*} (1 - e^{-(k_2^* + k_3^*)t}) \otimes C_p^*(t)$$

# MODELLING OF GLUCOSE AND FDG METABOLISM:



Mass balance equations at  
metabolic steady-state:

$$\frac{dC_i(t)}{dt} = k_1 C_p + k_4 C_m - (k_2 + k_3) C_i = 0$$

$$\frac{dC_m(t)}{dt} = k_3 C_i - (k_4 C_m + CMR_{Glc}) = 0$$

$$CMR_{Glc} = k_3 C_i - k_4 C_m = C_p \frac{k_3 k_1}{k_2 + k_3}$$

$$MR_{Glc} = \frac{C_p}{LC} \frac{k_1^* k_3^*}{k_2^* + k_3^*}$$


with

$$LC = \frac{\left[ \frac{k_1^* k_3^*}{k_2^* + k_3^*} \right]}{\left[ \frac{k_1 k_3}{k_2 + k_3} \right]}$$

# MATHEMATICAL PRINCIPLES OF COMPARTMENTAL MODELLING

The measurement of the substrate concentration:

The arterial input function (AIF)




The AIF needs to be measured continuously over the entire infusion period or

The infusion protocol is designed to reach a desired input function.

# QUANTITATIVE CMR<sub>GLC</sub> MAPPING WITH PRECLINICAL PET

## Non-invasive tracer input function measurement



Research Article | Basic Science Investigations

## Image-Derived Input Function from the Vena Cava for <sup>18</sup>F-FDG PET Studies in Rats and Mice

Bernard Lanz<sup>1</sup>, Carole Poitry-Yamate<sup>2</sup>, and Rolf Gruetter<sup>1-4</sup>



<sup>1</sup>Laboratory for Functional and Metabolic Imaging (LIFMET), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland;

<sup>2</sup>Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; <sup>3</sup>Department of Radiology, University of Lausanne, Lausanne, Switzerland; and <sup>4</sup>Department of Radiology, University of Geneva, Geneva, Switzerland

THE JOURNAL OF NUCLEAR MEDICINE • Vol. 55 • No. 8 • August 2014

# QUANTITATIVE CMR<sub>GLC</sub> MAPPING WITH PRECLINICAL PET

## Non-invasive tracer input function measurement





PET images of vena cava in rat during first passage of <sup>18</sup>F-FDG bolus, used to define VOI for image-derived input function

Lanz et al., J. Nucl. Med., 2014



# INPUT FUNCTION DISPERSION / DELAY

## Characterization of the tracer dispersion:



Tracer dispersion is likely related to blood mixing in the pulmonary circulation and in interstitial tissue.



### Dispersion correction:

$$d(t) = a \left[ b(1/\tau_1) e^{-t/\tau_1} + (1-b)(1/\tau_2) e^{-t/\tau_2} \right]$$

*Lanz et al., J Nucl Med. 2014*

# QUANTITATIVE CMR<sub>GLC</sub> MAPPING WITH PRECLINICAL PET::

## APPLICATIONS [1]



Avalanche photodiode LabPET 4 scanner

Reconstruction:

- MLEM (5 iterations on vena cava ; 15 on brain)
- Built-in quantitative calibration on FDG phantom
- Correction for inelastic scattering and radioactive decay

Sokoloff approach: [4]

Quantitative 3D CMR<sub>glc</sub> maps

$$CMR_{glc}(T_f) = \frac{C_p}{LC} \frac{C_t^*(T_f)}{\int_0^{T_f} C_p^*(t) dt}$$

*Glycemia* →  $C_p$

$C_t^*(T_f)$

$\int_0^{T_f} C_p^*(t) dt$

*Lumped constant*  
0.71 [3]

**Minimal invasiveness (FDG injection + one blood sample)**

[1] Mosso et al., Anal. Biochem., 2022

[3] Tokugawa et al., J Nucl Med., 2007

[2] Lanz et al., J. Nucl. Med., 2014

[4] Sokoloff et al., J. Neurochem., 1977

# QUANTITATIVE $\text{CMR}_{\text{glc}}$ MAPPING WITH PRECLINICAL PET::

## APPLICATIONS <sup>[1]</sup> (HEPATIC ENCEPHALOPATHY)

### $\text{CMR}_{\text{glc}}$ maps

Slice number

12

14



16

18



$\text{CMR}_{\text{glc}}$   
( $\mu\text{mol/g/min}$ )

BDL

SHAM



Hippocampus



☑ glucose cerebral metabolic rate in BDL rats over all slices

- Limitations of the SUV when systemic metabolic effects occur
- Added power of quantitative mapping of glucose uptake ( $\text{CMR}_{\text{glc}}$ ) using an image-derived IF

# QUANTITATIVE $\text{CMR}_{\text{GLC}}$ MAPPING WITH PRECLINICAL PET


Minimally invasive metabolic flux measurement in rats and mice

- Image-derived tracer input function
- Calibrated PET images in Bq/ml
- Adapted metabolic modelling with dynamic (mice) or steady-state (rats) FDG radioactivity density maps

➡  $\text{CMR}_{\text{glc}}$  3D parametric maps with PET scanner nominal resolution  
(main limitation is the positron mean free path)

# QUANTITATIVE METABOLIC MODELLING





GOAL: compare, validate and combine multimodal results



# Deuterium MRSI





(also called DMI, deuterium metabolic imaging)

- Labelling experiment to study metabolic pathways (like in FDG-PET or  $^{13}\text{C}$  MRS)
- Low background signal (water lipids)
- Short relaxation times ( $T_1$  and  $T_2$ )  
-> faster temporal averages



rat brain in vivo at 11.7 T  
before infusion of any  
 $^2\text{H}$ -labeled substrate

rat brain after infusion  
of  $[6,6'\text{-}^2\text{H}_2]\text{glucose}$  in vivo



De Feyter *et al.*, *Sci. Adv.* 2018




# Deuterium MRSI

(also called DMI, deuterium metabolic imaging)

- Labelling experiment to study metabolic pathways (like in FDG-PET or  $^{13}\text{C}$  MRS)
- Low background signal (water lipids)
- Short relaxation times ( $T_1$  and  $T_2$ )  
-> faster temporal averages

Specific challenges:


- label losses
- Isotopic effects



rat brain in vivo at 11.7 T  
before infusion of any  
 $^2\text{H}$ -labeled substrate

rat brain after infusion  
of  $[6,6'\text{-}^2\text{H}_2]\text{glucose}$  in vivo


De Feyter *et al.*, *Sci. Adv.* 2018



De Graaf *et al.*, *ACS Chem. Neurosci.* 2021

# Towards quantitative Deuterium MRSI

- Deuterium MRSI : **intermediary spatial resolution** as compared to FDG-PET and in vivo  $^{13}\text{C}$  MRS (one single voxel)
- It is able to distinguish  $\text{CMR}_{\text{Glc}}(\text{ox})$  et  $\text{CMR}_{\text{Glc}}(\text{non-ox})$  (chemical specificity)
- It is non-radioactive and safe (strong clinical potential)
- Further developments need to be done to acquire metabolic maps dynamically
  - > new spatial encoding strategies
  - > obtain metabolic time courses for each voxel
  - > derive  $\text{CMR}_{\text{Glc}}(\text{ox})$  et  $\text{CMR}_{\text{Glc}}(\text{non-ox})$  in micromol/g/min
- Validate results in preclinical experiments with FDG-PET et  $^{13}\text{C}$  MRS







# BIBLIOGRAPHY

Contact: [bernard.lanz@epfl.ch](mailto:bernard.lanz@epfl.ch)

- Cudalbu, C. & Lanz, B.  
Methods | Magnetic Resonance Spectroscopy for the Measurement of In Vivo Brain Metabolism. in *Encyclopedia of Biological Chemistry III (Third Edition)* (ed. Jez, J.) (Elsevier, 2021). doi:10.1016/B978-0-12-819460-7.00295-4.
- Lai, M., Gruetter, R. & Lanz, B.  
Progress towards in vivo brain  $^{13}\text{C}$ -MRS in mice: Metabolic flux analysis in small tissue volumes. *Anal Biochem* **529**, 229–244 (2017).
- Cobelli, C., Foster, D. and Toffolo, G. (2007) *Tracer kinetics in biomedical research: from data to model*, Kluwer Academic Publishers.
- Berliner, L. J. and Robitaille, P. M. (2002) *In vivo carbon-13 NMR*, Kluwer Academic Publishers.
- [http://infoscience.epfl.ch/record/182628/files/EPFL\\_TH5468.pdf](http://infoscience.epfl.ch/record/182628/files/EPFL_TH5468.pdf)



# Thank you for your attention

Contact: [bernard.lanz@epfl.ch](mailto:bernard.lanz@epfl.ch)

